Phase 2 Study - Aurora + Angiogenic Kinase Inhibitor ENMD-2076 in Previously Treated Locally Advanced + Metastatic TNBC

Clinical trial NCT01639248 · COMPLETED

Trial details

NCT number: NCT01639248
Sponsor: CASI pharmaceuticals, Inc.
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Triple Negative Breast Cancer

Start date: 2012-07-01
Primary completion: 2017-06-01
Enrollment: 41

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.